Tesa Chemical

RESEARCH GRID / CITATION REGISTER

Tesamorelin references: the studies behind every figure

Each quantitative claim on this site maps to a numbered entry below — peer-reviewed trials, pharmacokinetic analyses, the NIH LiverTox monograph, and the FDA prescribing information.

Back to the researchPharmacokinetics

Cited sources

Every figure cited across this tesamorelin digest resolves to one of the numbered references below. Primary trials are listed with PubMed identifiers and DOIs; the regulatory and drug-safety sources link to the FDA prescribing information and the NIH LiverTox monograph. This site is an editorial summary of these published sources; the numbered study references below are the basis for every figure, with deeper context on the visceral-fat research and tesamorelin half-life pages.

  1. Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. ↗
  2. Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-1728. ↗
  3. Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. ↗
  4. Stanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. ↗
  5. National Institute of Diabetes and Digestive and Kidney Diseases. Tesamorelin — LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. NCBI Bookshelf (NIH); 2018. ↗
  6. Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015;54(3):285-294. ↗
  7. Gonzalez-Sales M, Barriere O, Tremblay PO, Nekka F, Mamputu JC, Boudreault S, Tanguay M. Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects. J Pharmacokinet Pharmacodyn. 2015;42(3):287-299. ↗
  8. Ferdinandi ES, Brazeau P, High K, Procter B, Fennell S, Dubreuil P. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100:49-58. ↗
  9. Jansen M, Darby I, Abribat T, Dubreuil P, Ferdinandi ES, Hardy JG. Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. Int J Pharm. 2004;276:75-81. ↗
  10. Teng S, et al. Impact of tesamorelin, a growth hormone-releasing factor (GRF) analogue, on the pharmacokinetics of simvastatin and ritonavir in healthy volunteers. Clin Pharmacol Drug Dev. 2013;2:237-245. ↗
  11. Kanashiro-Takeuchi RM, Takeuchi LM, et al. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci U S A. 2012;109:559-563. ↗
  12. Yen DW, Sherman KE. Causes and outcomes of hepatic fibrosis in persons living with HIV. Curr Opin HIV AIDS. 2022;17:359-367. ↗
  13. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. ↗
  14. Arora G, Conde KR, Desouza CV. Pharmacologic treatments for the preservation of lean body mass during weight loss. J Clin Med. 2026;15(2):541. ↗
  15. Mayfield CK, et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. 2026. ↗